✦ LIBER ✦

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients

✍ Scribed by M.S.Y. Goh; C. McCormack; H.V. Dinh; B. Welsh; P. Foley; H.M. Prince

Book ID: 108669347
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 783 KB
Volume: 156
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2007.07800.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in the treatment of dermatomyo

Rituximab in the treatment of dermatomyositis: An open-label pilot study

✍ Todd D. Levine 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Influence of Rituximab on markers of bon

Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study

✍ Gert Hein; Thorsten Eidner; Peter Oelzner; Michael Rose; Alexander Wilke; Gunter 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 232 KB

Open-label use of placebos in the treatm

Open-label use of placebos in the treatment of ADHD: a pilot study

✍ A. D. Sandler; J. W. Bodfish 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Duloxetine in the treatment of irritable

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study

✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal

Atomoxetine for the treatment of executi

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study

✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Open-label pilot study of levetiracetam

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo